2. Academic Validation
  3. Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach

Dissecting humoral immune responses to an MVA-vectored MERS-CoV vaccine in humans using a systems serology approach

  • iScience. 2024 Jul 8;27(8):110470. doi: 10.1016/j.isci.2024.110470.
Leonie M Weskamm 1 2 3,  Paulina Tarnow 1 2 3,  Charlotte Harms 4 5,  Melanie Huchon 6 7,  Matthijs P Raadsen 8,  Monika Friedrich 1 2 3,  Laura Rübenacker 1 2 3,  Cordula Grüttner 1 2 3,  Mariana G Garcia 4 5,  MVA-MERS-S-CEF study group,  Till Koch 1 3 9,  Stephan Becker 10 11,  Gerd Sutter 12 13,  Edouard Lhomme 6 7 14,  Bart L Haagmans 8,  Anahita Fathi 1 2 3 15,  Sandra M Blois 4 5,  Christine Dahlke 1 2 3,  Laura Richert 6 7 14,  Marylyn M Addo 1 2 3
Affiliations

Affiliations

  • 1 Institute for Infection Research and Vaccine Development (IIRVD), Center for Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • 2 Department for Clinical Immunology of Infectious Diseases, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
  • 3 German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Hamburg, Germany.
  • 4 Department of Obstetrics and Fetal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • 5 Glyco-HAM, a Cooperation of Universität Hamburg, Technology Platform Mass Spectrometry and University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • 6 University of Bordeaux, INSERM, INRIA, BPH, U1219, Sistm, Bordeaux, France.
  • 7 Vaccine Research Institute, Creteil, France.
  • 8 Department of Viroscience, Erasmus University Medical Center, Rotterdam, the Netherlands.
  • 9 Antibiotic Stewardship Team, Pharmacy of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • 10 Institute of Virology, Philipps University Marburg, Marburg, Germany.
  • 11 German Center for Infection Research, Partner Site Gießen-Marburg-Langen, Marburg, Germany.
  • 12 Division of Virology, Department of Veterinary Sciences, Ludwig Maximilian University Munich, Munich, Germany.
  • 13 German Center for Infection Research, Partner Site München, Munich, Germany.
  • 14 CHU de Bordeaux, Service d'Information Médicale, Bordeaux, France.
  • 15 Division of Infectious Diseases, 1st Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
PMID: 39148710 DOI: 10.1016/j.isci.2024.110470
Abstract

Besides neutralizing Antibodies, which are considered an important measure for vaccine immunogenicity, Fc-mediated antibody functions can contribute to antibody-mediated protection. They are strongly influenced by structural antibody properties such as subclass and Fc glycan composition. We here applied a systems serology approach to dissect humoral immune responses induced by MVA-MERS-S, an MVA-vectored vaccine against the Middle East respiratory syndrome coronavirus (MERS-CoV). Building on preceding studies reporting the safety and immunogenicity of MVA-MERS-S, our study highlights the potential of a late boost, administered one year after prime, to enhance both neutralizing and Fc-mediated antibody functionality compared to the primary vaccination series. Distinct characteristics were observed for Antibodies specific to the MERS-CoV spike protein S1 and S2 subunits, regarding subclass and glycan compositions as well as Fc functionality. These findings highlight the benefit of a late homologous booster vaccination with MVA-MERS-S and may be of interest for the design of future coronavirus vaccines.

Keywords

Cell biology; Immune response; Immunology; Virology.

Figures
Products